MS
At a glance
Registered since
2024
Senate LDA system
Clients
1
last 3 years
Filings
4
1 agencies contacted
Activity
filings by quarter
Works on
Specific issues
Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilar Red Tape Elimination Act (S.2305); Give Kids a Chance Act of 2023 (H.R. 3433/S.2897); Affordable Prescriptions for Patients Act of 2023 (S. 150); S.3583/H.R. 6986, A bill to address patent thickets; Medication Affordability and Patent Integrity Act (S.2780); Stop STALLING Act (S. 148); S.5573 - A bill to amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products; H.R.3839 - To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications; Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025 (H.R. 10445); FDA Modernization Act 3.0 (H.R. 7248); Promising Pathway Act (H.R. 3761/S. 1644); BIOSECURE Act (H.R. 7085); Section 851 (Prohibition on Contracting with Covered Entities that Contract with Lobbyists for Chinese Military Companies) of the Fiscal Year 2024 National Defense Authorization bill ((H.R. 5009/S. 4638); Biotechnological Innovation and Opportunity for Competitive Economic Transformation Act of 2024 (BioCompete) ; clinical trial diversity; rare diseases; patent listing; rare pediatric disease priority review vouchers.
S.5573 - A bill to amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products; S.3583/H.R. 6986, A bill to address patent thickets; Affordable Prescriptions for Patients Act of 2023 (S. 150); Patent Eligibility Restoration Act (PERA) (S. 2140); Biopharmaceutical innovation and intellectual property policy issues.
Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Innovation in Pediatric Drugs Act of 2023 (H.R. 6664); Biosimilar Red Tape Elimination Act (S.2305); Give Kids a Chance Act of 2023 (H.R. 3433/S.2897); Affordable Prescriptions for Patients Act of 2023 (S. 150); Induced infringement and generic drug labeling; S.3583/H.R. 6986, A bill to address patent thickets; REMEDY Act (S. 1209); Medication Affordability and Patent Integrity Act (S.2780); rare pediatric disease priority review vouchers; Stop STALLING Act (S. 148); Interagency Patent Coordination and Improvement Act of 2023 (S. 79); Preserve Access to Affordable Generics and Biosimilars Act (S. 142); Bayh-Dole; Biosecure Act (H.R. 7085, H.R. 8333, S. 3385); and The Federal Acquisition Security Council Improvement Act (discussion draft).
Induced infringement and generic drug labeling; S.3583/HR 6986, A bill to address patent thickets; Affordable Prescriptions for Patients Act of 2023 (S. 150); Biopharmaceutical innovation and intellectual property policy issues.
Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Innovation in Pediatric Drugs Act of 2023 (H.R. 6664); Biosimilar Red Tape Elimination Act (S. 2305); Give Kids a Chance Act of 2023 (H.R. 3433/S.2897); Affordable Prescriptions for Patients Act of 2023 (S. 150); Induced infringement and generic drug labeling; S.3583/H.R. 6986, A bill to address patent thickets; REMEDY Act (S. 1209); FDA Modernization Act 3.0 (H.R. 7248); Increasing Transparency in Generic Drug Applications Act (S. 775); Medication Affordability and Patent Integrity Act (S. 2780); Patent listing; Requirements for generic drug-device combination products; priority review vouchers; 3-year exclusivity; Biosecure Act (H.R. 7085, H.R. 8333, S. 3385); Biotechnological Innovation and Opportunity for Competitive Economic Transformation Act of 2024 (BioCompete); Invent Here, Make Here (S. 1956).
Induced infringement and generic drug labeling; S.3583/H.R. 6986, A bill to address patent thickets; Affordable Prescriptions for Patients Act of 2023 (S. 150); Biopharmaceutical innovation and intellectual property policy issues.